Intra-Cellular Therapies (ITCI) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ITCI Intra-Cellular Therapies

Watchlist

72.130
-0.990-1.35%

Close Apr 25 16:00 ET

72.130
0.0000.00%

Post 16:20 ET

7.53BMarket Cap-49404P/E (TTM)

Post-Market

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Press Release: Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- I
Dow JonesApr 24 16:01 ET
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and maintains $120 price target.
BenzingaApr 24 09:57 ET
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)
TipRanksApr 24 08:50 ET
Intra-Cellular Therapies Is Maintained at Buy by Canaccord Genuity
Intra-Cellular Therapies Is Maintained at Buy by Canaccord Genuity
Dow JonesApr 23 10:58 ET
Express News | Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $107
Moomoo 24/7Apr 23 10:49 ET
Express News | Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90
Moomoo 24/7Apr 22 12:44 ET

Comments

Meltyy

Apr 1 15:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$Hutchmed (China)(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...

Moomoo AI

Mar 27 23:03

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

Market Sentiment Around Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Meltyy

Mar 22 10:48

Mental Health Biotech Catalyst Watchlist

$Vanda Pharmaceuticals(VNDA.US)$ PDUFA
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$Bristol-Myers Squibb(BMY.US)$ PDUFA
$Alzamend Neuro(ALZN.US)$ Phase 2
$Alzamend Neuro(ALZN.US)$ Phase 2a

Meltyy

Feb 22 12:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US)$ Phase 3
$Palatin Technologies(PTN.US)$ Phase 3
$Annovis Bio(ANVS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Atea Pharmaceuticals(AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 3
$Axsome Therapeutics(AXSM.US)$ Phase 3
$$Novocure(NVCR.US)$ Phase 3
$ROCHE HOLDING AG(RHHBY.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US)$ Phase 3
$Sellas Life Sciences(SLS.US)$...

Moomoo AI

Feb 14 22:15

The market seems optimistic about Intra-Cellular Therapies, Inc. given its strong revenue growth and share price momentum. It's recommended to take a closer look at this stock.